Regadenoson stress in patients with asthma and COPD: a breath of fresh air.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Assessing the Real-World Safety of Regadenoson for Myocardial Perfusion Imaging: Insights from a Comprehensive Analysis of FAERS Data.Journal of clinical medicine · 2025
   Article
2. Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthma.European journal of nuclear medicine and molecular imaging · 2014
   Observational
3. Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge.International journal of chronic obstructive pulmonary disease · 2014
   Review
4. Regadenoson: a focused update.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2013
   Review

Corrections and comments

• Comment on
  A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as